迟发性运动障碍治疗市场规模、份额和成长分析（按治疗方法、药物、给药途径、最终用户、分销管道和地区划分）－2026-2033年产业预测

全球迟发性运动障碍治疗市场规模预计在 2024 年达到 38.8 亿美元，从 2025 年的 41.8 亿美元增长到 2033 年的 76.3 亿美元，在预测期（2026-2033 年）内复合年增长率为 7.8%。

受思觉失调症和躁郁症等精神疾病盛行率上升的推动，全球迟发性运动障碍治疗市场预计将持续成长。这些疾病通常需要长期抗精神病药物治疗，并可能导致迟发性运动障碍。 VMAT2抑制剂疗法的进展以及监管机构对加速核准的支持进一步提升了市场潜力。新兴国家医疗基础设施的扩建改善了神经精神疾病患者的就医途径，而人们对迟发性运动障碍的认识不断提高，也推动了相关治疗的普及。然而，治疗成本上升、现有疗法的潜在副作用、发展中地区认知度不足以及患者群体较小导致研发投入有限等挑战，可能会在短期内阻碍市场扩张。

推动全球迟发性运动障碍治疗市场发展的因素

全球迟发性运动障碍治疗市场主要受监管机构积极措施的推动，尤其是那些旨在加速新型治疗方法核准流程、以满足该疾病未满足需求的措施。这些加速审批的途径，包括简审类和优先审评，激励製药公司推动创新治疗方法的研发。因此，这种监管支持不仅提高了有前景的候选药物快速进入市场的机会，也促进了这一重要医疗领域的投资和创新，从而对全球迟发性运动障碍治疗市场的整体前景产生了积极影响。

全球迟发性运动障碍治疗市场面临的限制因素

全球迟发性运动障碍治疗市场面临严峻挑战，主要原因是VMAT2抑制剂（常用的迟发性运动障碍治疗药物）的副作用。患者常出现疲劳、忧郁和嗜睡等症状，严重影响治疗顺从性和整体生活品质。这些不良反应可能导致部分患者选择完全停止治疗。此外，由于担心这些药物的长期安全性，医疗机构可能不愿意开立此类药物。因此，这些因素共同导致迟发性运动障碍有效治疗方法的推广应用缓慢。

迟发性运动障碍治疗市场的全球趋势

全球迟发性运动障碍治疗市场正经历显着的成长趋势，这主要得益于VMAT2抑制剂疗法的进步。Valbenazine和Tetrabenazine等药物的问世改变了治疗模式，它们能够更有效标靶治疗缓解迟发性运动障碍的症状，并显着提高疗效和安全性。此外，诸如Ingleza Sprinkle等创新剂型满足了患者的需求，尤其是那些吞嚥困难的患者，从而有助于提高治疗依从性和整体治疗效果。这种以患者为中心的先进治疗方法研发模式，使VMAT2抑制剂成为市场基石，并预示着未来将出现更多针对这种棘手疾病的高效且易于获得的治疗方案。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 案例研究

全球迟发性运动障碍治疗市场规模（依疗法和复合年增长率划分）（2026-2033 年）

• 药物治疗
• 手术治疗

全球迟发性运动障碍治疗市场规模（依药物类别划分）及复合年增长率（2026-2033 年）

• 抗精神病药物
• VMAT2抑制剂
• 肉毒桿菌毒素
• 自然疗法
• 多巴胺耗竭药物
• 其他的

全球迟发性运动障碍治疗市场规模（依给药途径及复合年增长率划分）（2026-2033 年）

• 口服
• 注射

全球迟发性运动障碍治疗市场规模（以最终用户划分）及复合年增长率（2026-2033 年）

• 医院
• 居家医疗
• 专科诊所
• 其他的

全球迟发性运动障碍治疗市场规模（依通路划分）及复合年增长率（2026-2033 年）

• 医院药房
• 零售药房
• 其他的

全球迟发性运动障碍治疗市场规模及复合年增长率（2026-2033）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2023-2025年营收年比比较

主要企业简介

• Neurocrine Biosciences, Inc.（US）
• Teva Pharmaceutical Industries Ltd.（Israel）
• H. Lundbeck A/S（Denmark）
• AbbVie Inc.（US）
• Otsuka Holdings Co., Ltd.（Japan）
• Astellas Pharma Inc.（Japan）
• Bausch Health Companies Inc.（Canada）
• Sumitomo Pharma America, Inc（US）
• Reviva Pharmaceuticals Holdings, Inc.（US）
• Acadia Pharmaceuticals Inc.（US）
• VANDA PHARMACEUTICALS（US）
• Eisai Co., Ltd.（Japan）
• Zydus Group（India）
• Lilly（US）
• F. Hoffmann-La Roche Ltd（Switzerland）
• Pfizer Inc.（US）
• Bristol-Myers Squibb Company（US）
• Mallinckrodt（US）

结论与建议

Global Tardive Dyskinesia Treatment Market size was valued at USD 3.88 Billion in 2024 and is poised to grow from USD 4.18 Billion in 2025 to USD 7.63 Billion by 2033, growing at a CAGR of 7.8% during the forecast period (2026-2033).

The global tardive dyskinesia treatment market is poised for growth driven by the rising prevalence of psychiatric disorders like schizophrenia and bipolar disorder, which often necessitate long-term antipsychotic treatment, leading to tardive dyskinesia. Advances in VMAT2 Inhibitor therapies and regulatory support for accelerated approvals further enhance market potential. Increased healthcare infrastructure in emerging economies is facilitating better access to neurological and psychiatric care, while growing awareness of tardive dyskinesia is promoting treatment adoption. However, challenges such as high treatment costs, potential adverse side effects of existing therapies, low awareness in developing regions, and limited research and development investment due to a small patient population may hinder market expansion in the foreseeable future.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Tardive Dyskinesia Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Tardive Dyskinesia Treatment Market Segments Analysis

Global Tardive Dyskinesia Treatment Market is segmented by Treatment, Drugs, Route of administration, End User, Distribution Channel and region. Based on Treatment, the market is segmented into Medication and Surgery. Based on Drugs, the market is segmented into Antipsychotics, VMAT2 Inhibitors, Botulinum Toxin, Natural Remedies, Dopamine-Depleting Medications and Others. Based on Route of administration, the market is segmented into Oral and Injectable. Based on End User, the market is segmented into Hospitals, Homecare, Specialty Clinics and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Tardive Dyskinesia Treatment Market

The Global Tardive Dyskinesia Treatment market is significantly driven by the proactive measures taken by regulatory authorities, particularly in facilitating faster approval processes for new therapies aimed at addressing the unmet medical needs associated with this condition. These expedited pathways, which include fast-track designations and priority reviews, encourage pharmaceutical companies to pursue the development of innovative treatments. As a result, this regulatory support not only enhances the likelihood of rapid market entry for promising drug candidates but also positively influences the overall outlook for the global tardive dyskinesia treatment market by stimulating investment and innovation in this critical area of healthcare.

Restraints in the Global Tardive Dyskinesia Treatment Market

The Global Tardive Dyskinesia Treatment market faces notable challenges due to the side effects associated with VMAT2 inhibitors, which are commonly used to manage this condition. Patients often experience fatigue, depression, and somnolence, significantly affecting their adherence to treatment regimens and overall quality of life. These adverse effects can lead to some patients opting to discontinue their therapy altogether. Furthermore, healthcare providers may exhibit reluctance in prescribing these medications due to concerns regarding their long-term safety profiles. Consequently, these factors collectively contribute to a slower adoption of effective treatment options for tardive dyskinesia.

Market Trends of the Global Tardive Dyskinesia Treatment Market

The Global Tardive Dyskinesia Treatment market is witnessing a significant trend driven by advancements in VMAT2 inhibitor therapies. The emergence of medications like valbenazine and deutetrabenazine has transformed the treatment landscape, offering targeted relief from the symptoms of tardive dyskinesia with enhanced efficacy and safety. Innovative formulations, such as Ingrezza Sprinkle, further address patient needs, specifically those with swallowing difficulties, thereby improving treatment adherence and overall outcomes. This focus on developing sophisticated and patient-centric therapies positions VMAT2 inhibitors as a cornerstone of the market, suggesting a future trend towards more effective and accessible treatment options for this challenging condition.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies

Global Tardive Dyskinesia Treatment Market Size by Treatment & CAGR (2026-2033)

• Market Overview
• Medication
• Surgery

Global Tardive Dyskinesia Treatment Market Size by Drugs & CAGR (2026-2033)

• Market Overview
• Antipsychotics
• VMAT2 Inhibitors
• Botulinum Toxin
• Natural Remedies
• Dopamine-Depleting Medications
• Others

Global Tardive Dyskinesia Treatment Market Size by Route of administration & CAGR (2026-2033)

• Market Overview
• Oral
• Injectable

Global Tardive Dyskinesia Treatment Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Homecare
• Specialty Clinics
• Others

Global Tardive Dyskinesia Treatment Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Others

Global Tardive Dyskinesia Treatment Market Size & CAGR (2026-2033)

• North America (Treatment, Drugs, Route of administration, End User, Distribution Channel)
  • US
  • Canada
• Europe (Treatment, Drugs, Route of administration, End User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment, Drugs, Route of administration, End User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment, Drugs, Route of administration, End User, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment, Drugs, Route of administration, End User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Neurocrine Biosciences, Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• H. Lundbeck A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Otsuka Holdings Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bausch Health Companies Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sumitomo Pharma America, Inc (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Reviva Pharmaceuticals Holdings, Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Acadia Pharmaceuticals Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• VANDA PHARMACEUTICALS (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eisai Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Group (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lilly (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mallinckrodt (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations